Earnings Call
Aug 4, 2026
Q2 FY2026
EPS Estimate
-0.27
EPS Actual
-0.13
Post-Earnings Close
$128.00
Earnings Reaction
+0.2%
Merck's second quarter came in at $16.6 billion in revenue, up 5% reported and 4% ex-FX, beating the consensus estimate and prompting management to raise and narrow full-year revenue guidance to $66.3, $67.3 billion. The headline EPS loss of $0.13 per share reflects a $2.31 per-share non-cash charge from the acquisition of Terns Pharmaceuticals, which added MK-4208, a potentially best-in-class CML therapy, to the hematology pipeline. Stripping out that charge, the underlying business performed solidly, and the company reiterated its adjusted EPS guidance midpoint of $2.71 for the full year.
Report generated on Aug 4, 2026
AI-generated earnings analysis. Not investment advice.
Chief Executive Officer
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
Read the full MRK analysis
The complete report, with key themes, analyst Q&A summary, notable quotes, and market context — is free with an account. No password, no card.